NCR3LG1 and neoplasm: The data published by Hua et al. and Gacerez et al. report the development of fully humanized scFvs targeting high B7H6-expressing tumors and thus focus on scFvs for anti-B7H6 CARs that potentially spare non-tumor cells expressing low levels of B7H6 [53,54].